Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Quenel-Tueux N, Debled M, Rudewicz J, MacGrogan G, Pulido M, Mauriac L, Dalenc F, Bachelot T, Lortal B, Breton-Callu C, Madranges N, de Lara CT, Fournier M, Bonnefoi H, Soueidan H, Nikolski M, Gros A, Daly C, Wood H, Rabbitts P, Iggo R

Open source

DOI: 10.1038/bjc.2015.247
Published: 2015 Aug 11
Container: British journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/bjc.2015.247,
  title = {Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.},
  author = {Quenel-Tueux N and Debled M and Rudewicz J and MacGrogan G and Pulido M and Mauriac L and Dalenc F and Bachelot T and Lortal B and Breton-Callu C and Madranges N and de Lara CT and Fournier M and Bonnefoi H and Soueidan H and Nikolski M and Gros A and Daly C and Wood H and Rabbitts P and Iggo R},
  year = {2015},
  journal = {British journal of cancer},
  doi = {10.1038/bjc.2015.247},
  url = {https://doi.org/10.1038/bjc.2015.247}
}

RIS

TY  - JOUR
TI  - Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
AU  - Quenel-Tueux N
AU  - Debled M
AU  - Rudewicz J
AU  - MacGrogan G
AU  - Pulido M
AU  - Mauriac L
AU  - Dalenc F
AU  - Bachelot T
AU  - Lortal B
AU  - Breton-Callu C
AU  - Madranges N
AU  - de Lara CT
AU  - Fournier M
AU  - Bonnefoi H
AU  - Soueidan H
AU  - Nikolski M
AU  - Gros A
AU  - Daly C
AU  - Wood H
AU  - Rabbitts P
AU  - Iggo R
PY  - 2015
JO  - British journal of cancer
DO  - 10.1038/bjc.2015.247
UR  - https://doi.org/10.1038/bjc.2015.247
ER  -

APA

N, Q., M, D., J, R., G, M., M, P., L, M., F, D., T, B., B, L., C, B., N, M., CT, D. L., M, F., H, B., H, S., M, N., A, G., C, D., H, W., P, R., & R, I. (2015). Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.. British journal of cancer. https://doi.org/10.1038/bjc.2015.247

Source records

pubmed · retrieved 2026-09-26T12:22:05.730Z